Systems and methods for integrated glycerol carbonate and/or urea production. This disclosure pertains to development of a process for production of glycerol carbonate and/or urea from ammonia, carbon dioxide and glycerol. The process integrates glycerol carbonate production into a urea production process. The urea produced in the production facility may be used to produce glycerol carbonate by reacting urea with glycerol. The ammonia generated by glycerol carbonate production may be recycled back to urea production. Unreacted urea from the glycerol carbonate production may be separated and recycled to the urea product stream. The systems and methods can reduce the cost for urea production and increase product value of the excessive glycerol produced from other chemical plants.

Systems and methods for integrated glycerol carbonate and/or urea production. This disclosure pertains to development of a process for production of glycerol carbonate and/or urea from ammonia, carbon dioxide and glycerol. The process integrates glycerol carbonate production into a urea production process. The urea produced in the production facility may be used to produce glycerol carbonate by reacting urea with glycerol. The ammonia generated by glycerol carbonate production may be recycled back to urea production. Unreacted urea from the glycerol carbonate production may be separated and recycled to the urea product stream. The systems and methods can reduce the cost for urea production and increase product value of the excessive glycerol produced from other chemical plants.

Systems and methods for integrated glycerol carbonate and/or urea production. This disclosure pertains to development of a process for production of glycerol carbonate and/or urea from ammonia, carbon dioxide and glycerol. The process integrates glycerol carbonate production into a urea production process. The urea produced in the production facility may be used to produce glycerol carbonate by reacting urea with glycerol. The ammonia generated by glycerol carbonate production may be recycled back to urea production. Unreacted urea from the glycerol carbonate production may be separated and recycled to the urea product stream. The systems and methods can reduce the cost for urea production and increase product value of the excessive glycerol produced from other chemical plants.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

The invention provides methods of synthesizing compounds in an asymmetric or enantioenriched fashion, wherein the compounds are useful intermediates in the synthesis of viral protease inhibitors.

The invention provides methods of synthesizing compounds in an asymmetric or enantioenriched fashion, wherein the compounds are useful intermediates in the synthesis of viral protease inhibitors.